“Generalized Pustular Psoriasis (GPP) Control is Limited on Traditional Small-molecule Therapy as Measured by the GPP Physician Global Assessment (GPPGA) and Dermatology Life Quality Index (DLQI): Baseline Data from the EFFISAYIL® 2 Trial” (2025) SKIN The Journal of Cutaneous Medicine, 9(2), p. s540. doi:10.25251/skin.10.supp.540.